Synthesis and cytostatic evaluation of 4-N-alkanoyl and 4-N-alkyl gemcitabine analogues

Journal of Medicinal Chemistry

Volumn 57, Issue 1, 2014, Pages 191-203

  Pulido, Jesse ^a   Sobczak, Adam J ^a   Balzarini, Jan ^b   Wnuk, Stanislaw F ^a  

^a FLORIDA INTERNATIONAL UNIVERSITY   (United States)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

2 DEOXYCYTIDINE KINASE; 4 N (10 FLUOROUNDECANOYL) 2' DEOXY 2',2' DIFLUOROCYTIDINE; 4 N (10 UNDECANOYL) 2' DEOXY 2',2' DIFLUOROCYTIDINE; 4 N (10 UNDECENYL) 2' DEOXY 2',2' DIFLUOROCYTIDINE; 4 N (11 BENZLOXYUNDECANYL) 2' DEOXY 2',2' DIFLUOROCYTIDINE; 4 N (11 BROMOUNDECANOYL) 2' DEOXY 2',2' DIFLUOROCYTIDINE; 4 N (11 CHLOROUNDECANOYL) 2' DEOXY 2',2' DIFLUOROCYTIDINE; 4 N (11 FLUOROUNDECANOYL) 2' DEOXY 2',2' DIFLUOROCYTIDINE; 4 N (11 HYDROXYUNDECANOYL) 2' DEOXY 2',2' DIFLUOROCYTIDINE; 4 N (11 HYDROXYUNDECANYL) 2' DEOXY 2',2' DIFLUOROCYTIDINE; 4 N (8 NONENOYL) 2' DEOXY 2',2' DIFLUOROCYTIDINE; 4 N (TRIDECENOYL) 2' DEOXY 2',2' DIFLUOROCYTIDINE; 4 N (UNDECANOYL) 2' DEOXY 2',2' DIFLUOROCYTIDINE; 4 N [11 (1H BENZOTRIAZOL 1 YLOXY) UNDECANOYL] 2' DEOXY 2',2' DIFLUOROCYTIDINE; 4 TOSYLGEMCITABINE; AMINE; CARBOXYLIC ACID DERIVATIVE; CYTOSTATIC AGENT; DEOXYCYTIDINE KINASE; GEMCITABINE; GEMCITABINE DERIVATIVE; HYDROXYL GROUP; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CYTOSTASIS; CYTOTOXICITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DEOXYCYTIDINE; HUMANS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84892608365     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm401586a     Document Type: Article

References (56)

1. Gesto, D. S.; Cerqueira, N. M.; Fernandes, P. A.; Ramos, M. J. Gemcitabine: A critical nucleoside for cancer therapy Curr. Med. Chem. 2012, 19, 1076-1087
2. Toschi, L.; Finocchiaro, G.; Bartolini, S.; Gioia, V.; Cappuzzo, F. Role of gemcitabine in cancer therapy Future Oncol. 2005, 1, 7-17
3. Hertel, L. W.; Kroin, J. S.; Misner, J. W.; Tustin, J. M. Synthesis of 2-deoxy-2,2-difluoro- d -ribose and 2-deoxy-2,2′-difluoro- d -ribofuranosyl nucleosides J. Org. Chem. 1988, 53, 2406-2409
4. Voutsadakis, I. A. Molecular predictors of gemcitabine response in pancreatic cancer World J. Gastrointest. Oncol. 2011, 3, 153-164
5. Ramalingam, S.; Belani, C. Systemic chemotherapy for advanced non-small cell lung cancer: Recent advances and future directions Oncologist 2008, 13, 5-13
6. Burris, H. A.; Moore, M. J.; Andersen, J.; Green, M. R.; Rothenberg, M. L.; Madiano, M. R.; Cripps, M. C.; Portenoy, R. K.; Storniolo, A. M.; Tarassoff, P.; Nelson, R.; Dorr, F. A.; Stephens, C. D.; VanHoff, D. D. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial J. Clin. Oncol. 1997, 15, 2403-2413
7. Mackey, J. R.; Mani, R. S.; Selner, M.; Mowles, D.; Young, J. D.; Belt, J. A.; Crawford, C. R.; Cass, C. E. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines Cancer Res. 1998, 58, 4349-4357
8. Heinemann, V.; Hertel, L. W.; Grindey, G. B.; Plunkett, W. Comparison of the cellular pharmacokinetics and toxicity of 2′,2′- difluorodeoxycytidine and 1-β- d -arabinofuranosylcytosine Cancer Res. 1988, 48, 4024-4031
9. Kroep, J. R.; van Moorsel, C. J.; Veerman, G.; Voorn, D. A.; Schultz, R. M.; Worzalla, J. F.; Tanzer, L. R.; Merriman, R. L.; Pinedo, H. M.; Peters, G. J. Role of deoxycytidine kinase (dCK), thymidine kinase 2 (TK2), and deoxycytidine deaminase (dCDA) in the antitumor activity of gemcitabine (dFdC) Adv. Exp. Med. Biol. 1998, 431, 657-660
10. Gandhi, V.; Plunkett, W. Modulatory activity of 2′,2′- difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleosides Cancer Res. 1990, 50, 3675-3680
11. Huang, P.; Chubb, S.; Hertel, L. W.; Grindey, G. B.; Plunkett, W. Action of 2′,2′-difluorodeoxycytidine on DNA-synthesis Cancer Res. 1991, 51, 6110-6117
12. Ruiz van Haperen, V. W. T.; Veerman, G.; Vermorken, J. B.; Peters, G. J. 2′,2′-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines Biochem. Pharmacol. 1993, 46, 762-766
13. Heinemann, V.; Schulz, L.; Issels, R. D.; Plunkett, W. Gemcitabine: A modulator of intracellular nucleotide and deoxynucleotide metabolism Semin. Oncol. 1995, 22, 11-18
14. Heinemann, V.; Xu, Y. Z.; Chubb, S.; Sen, A.; Hertel, L. W.; Grindey, G. B.; Plunkett, W. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-difluorodeoxycytidine Mol. Pharmacol. 1990, 38, 567-572
15. Plunkett, W.; Huang, P.; Xu, Y.-Z.; Heinemann, V.; Grunewald, R.; Gandhi, V. Gemcitabine: Metabolism, mechanisms of action, and self-potentiation Semin. Oncol. 1995, 22, 3-10
16. Baker, C. H.; Banzon, J.; Bollinger, J. M.; Stubbe, J.; Samano, V.; Robins, M. J.; Lippert, B.; Jarvi, E.; Resvick, R. 2′-Deoxy-2′- methylenecytidine and 2′-deoxy-2′,2′-difluorocytidine 5′-diphosphates: Potent mechanism-based inhibitors of ribonucleotide reductase J. Med. Chem. 1991, 34, 1879-1884
17. Silva, D. J.; Stubbe, J.; Samano, V.; Robins, M. J. Gemcitabine 5′-triphosphate is a stoichiometric mechanism-based inhibitor of Lactobacillus leichmannii ribonucleoside triphosphate reductase: Evidence for thiyl radical-mediated nucleotide radical formation Biochemistry 1998, 37, 5528-5535
18. van der Donk, W. A.; Yu, G. X.; Perez, L.; Sanchez, R. J.; Stubbe, J.; Samano, V.; Robins, M. J. Detection of a new substrate-derived radical during inactivation of ribonucleotide reductase from Escherichia coli by gemcitabine 5′-diphosphate Biochemistry 1998, 37, 6419-6426
19. Artin, E.; Wang, J.; Lohman, G. J. S.; Yokoyama, K.; Yu, G. X.; Griffin, R. G.; Bar, G.; Stubbe, J. Insight into the mechanism of inactivation of ribonucleotide reductase by gemcitabine 5′-diphosphate in the presence or absence of reductant Biochemistry 2009, 48, 11622-11629
20. Wang, J.; Lohman, G. J. S.; Stubbe, J. Mechanism of inactivation of human ribonucleotide reductase with p53R2 by gemcitabine 5′-diphosphate Biochemistry 2009, 48, 11612-11621
21. Shipley, L. A.; Brown, T. J.; Cornpropst, J. D.; Hamilton, M.; Daniels, W. D.; Culp, H. W. Metabolism and disposition of gemcitabine, and oncolytic deoxycytidine analog, in mice, rats, and dogs Drug Metab. Dispos. 1992, 20, 849-855
22. Patel, S. R.; Gandhi, V.; Jenkins, J.; Papadopolous, N.; Burgess, M. A.; Plager, C.; Plunkett, W.; Benjamin, R. S. Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation J. Clin. Oncol. 2001, 19, 3483-3489
23. Gandhi, V.; Plunkett, W.; Du, M.; Ayres, M.; Estey, E. H. Prolonged infusion of gemcitabine: Clinical and pharmacodynamic studies during a phase I trial in relapsed acute myelogenous leukemia J. Clin. Oncol. 2002, 20, 665-673
24. Jordheim, L. P.; Durantel, D.; Zoulim, F.; Dumontet, C. Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases Nat. Rev. Drug Discovery 2013, 12, 447-464
25. Bender, D. M.; Bao, J.; Dantzig, A. H.; Diseroad, W. D.; Law, K. L.; Magnus, N. A.; Peterson, J. A.; Perkins, E. J.; Pu, Y. J.; Reutzel-Edens, S. M.; Remick, D. M.; Starling, J. J.; Stephenson, G. A.; Vaid, R. K.; Zhang, D.; McCarthy, J. R. Synthesis, crystallization, and biological evaluation of an orally active prodrug of gemcitabine J. Med. Chem. 2009, 52, 6958-6961
26. Couvreur, P.; Stella, B.; Reddy, L. H.; Hillaireau, H.; Dubernet, C.; Desmaele, D.; Lepetre-Mouelhi, S.; Rocco, F.; Dereuddre-Bosquet, N.; Clayette, P.; Rosilio, V.; Marsaud, V.; Renoir, J. M.; Cattel, L. Squalenoyl nanomedicines as potential therapeutics Nano Lett. 2006, 6, 2544-2548
27. Dasari, M.; Acharya, A. P.; Kim, D.; Lee, S.; Lee, S.; Rhea, J.; Molinaro, R.; Murthy, N. H-Gemcitabine: A new gemcitabine prodrug for treating cancer Bioconjugate Chem. 2013, 24, 4-8
28. Immordino, M. L.; Brusa, P.; Rocco, F.; Arpicco, S.; Ceruti, M.; Cattel, L. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs J. Controlled Release 2004, 100, 331-346
29. Koolen, S. L.; Witteveen, P. O.; Jansen, R. S.; Langenberg, M. H.; Kronemeijer, R. H.; Nol, A.; Garcia-Ribas, I.; Callies, S.; Benhadji, K. A.; Slapak, C. A.; Beijnen, J. H.; Voest, E. E.; Schellens, J. H. Phase I study of oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients with advanced solid tumors Clin. Cancer Res. 2011, 17, 6071-6082
30. Pratt, S. E.; Durland-Busbice, S.; Shepard, R. L.; Heinz-Taheny, K.; Iversen, P. W.; Dantzig, A. H. Human carboxylesterase-2 hydrolyzes the prodrug of gemcitabine (LY2334737) and confers prodrug sensitivity to cancer cells Clin. Cancer Res. 2013, 19, 1159-1168
31. Rejiba, S.; Reddy, L. H.; Bigand, C.; Parmentier, C.; Couvreur, P.; Hajri, A. Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer Nanomedicine 2011, 7, 841-849
32. Wickremsinhe, E.; Bao, J.; Smith, R.; Burton, R.; Dow, S.; Perkins, E. Preclinical absorption, distribution, metabolism, and excretion of an oral amide prodrug of gemcitabine designed to deliver prolonged systemic exposure Pharmaceutics 2013, 5, 261-276
33. Bergman, A. M.; Adema, A. D.; Balzarini, J.; Bruheim, S.; Fichtner, I.; Noordhuis, P.; Fodstad, O.; Myhren, F.; Sandvold, M. L.; Hendriks, H. R.; Peters, G. J. Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models Invest. New Drugs 2011, 29, 456-466
34. Stuurman, F. E.; Voest, E. E.; Awada, A.; Witteveen, P. O.; Bergeland, T.; Hals, P. A.; Rasch, W.; Schellens, J. H.; Hendlisz, A. Phase I study of oral CP-4126, a gemcitabine derivative, in patients with advanced solid tumors Invest. New Drugs 2013, 31, 959-966
35. Maiti, S.; Park, N.; Han, J. H.; Jeon, H. M.; Lee, J. H.; Bhuniya, S.; Kang, C.; Kim, J. S. Gemcitabine-coumarin-biotin conjugates: A target specific theranostic anticancer prodrug J. Am. Chem. Soc. 2013, 135, 4567-4572
36. Bhuniya, S.; Lee, M. H.; Jeon, H. M.; Han, J. H.; Lee, J. H.; Park, N.; Maiti, S.; Kang, C.; Kim, J. S. A fluorescence off-on reporter for real time monitoring of gemcitabine delivery to the cancer cells Chem. Commun. 2013, 49, 7141-7143
37. Laing, R. E.; Walter, M. A.; Campbell, D. O.; Herschman, H. R.; Satyamurthy, N.; Phelps, M. E.; Czernin, J.; Witte, O. N.; Radu, C. G. Noninvasive prediction of tumor responses to gemcitabine using positron emission tomography Proc. Natl. Acad. Sci. U.S.A. 2009, 106, 2847-2852
38. Kroep, J. R.; Loves, W. J. P.; van der Wilt, C. L.; Alvarez, E.; Talianidis, L.; Boven, E.; Braakhuis, B. J. M.; van Groeningen, C. J.; Pinedo, H. M.; Peters, G. J. Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity Mol. Cancer Ther. 2002, 1, 371-376
39. Saiki, Y.; Yoshino, Y.; Fujimura, H.; Manabe, T.; Kudo, Y.; Shimada, M.; Mano, N.; Nakano, T.; Lee, Y.; Shimizu, S.; Oba, S.; Fujiwara, S.; Shimizu, H.; Chen, N.; Nezhad, Z. K.; Jin, G.; Fukushige, S.; Sunamura, M.; Ishida, M.; Motoi, F.; Egawa, S.; Unno, M.; Horii, A. DCK is frequently inactivated in acquired gemcitabine-resistant human cancer cells Biochem. Biophys. Res. Commun. 2012, 421, 98-104
40. Radu, C. G.; Shu, C. J.; Nair-Gill, E.; Shelly, S. M.; Barrio, J. R.; Satyamurthy, N.; Phelps, M. E.; Witte, O. N. Molecular imaging of lymphoid organs and immune activation by positron emission tomography with a new [(18)F]-labeled 2′-deoxycytidine analog Nature Med. 2008, 14, 783-788
41. Schwarzenberg, J.; Radu, C. G.; Benz, M.; Fueger, B.; Tran, A. Q.; Phelps, M. E.; Witte, O. N.; Satyamurthy, N.; Czernin, J.; Schiepers, C. Human biodistribution and radiation dosimetry of novel PET probes targeting the deoxyribonucleoside salvage pathway Eur. J. Nucl. Med. Mol. Imaging 2011, 38, 711-721
42. Lee, J. T.; Campbell, D. O.; Satyamurthy, N.; Czernin, J.; Radu, C. G. Stratification of nucleoside analog chemotherapy using 1-(2′-deoxy- 2′-F-18-fluoro-beta- d -arabinofuranosyl)cytosine and 1-(2′-deoxy- 2′-F-18-fluoro-beta- l -arabinofuranosyl)-5-methylcytosine PET J. Nucl. Med. 2012, 53, 275-280
43. Katritzky, A. R.; Suzuki, K.; Singh, S. K. N-Acylation in combinatorial chemistry ARKIVOC 2004, 12-35
44. Sinha, N. D.; Davis, P.; Schultze, L. M.; Upadhya, K. A simple method for N-acylation of adenosine and cytidine nucleosides using carboxylic acids activated in-situ with carbonyldiimidazole Tetrahedron Lett. 1995, 36, 9277-9280
45. Zhu, X. F.; Williams, H. J.; Scott, A. I. An improved transient method for the synthesis of N-benzoylated nucleosides Synth. Commun. 2003, 33, 1233-1243
46. Guo, Z. W.; Gallo, J. M. Selective protection of 2′,2′- difluorodeoxycytidine (gemcitabine) J. Org. Chem. 1999, 64, 8319-8322
47. Hugenberg, V.; Wagner, S.; Kopka, K.; Schober, O.; Schafers, M.; Haufe, G. Synthesis of geminal difluorides by oxidative desulfurization-difluorination of alkyl aryl thioethers with halonium electrophiles in the presence of fluorinating reagents and its application for 18F-radiolabeling J. Org. Chem. 2010, 75, 6086-6095
48. Bucsi, I.; Torok, B.; Marco, A. I.; Rasul, G.; Prakash, G. K.; Olah, G. A. Stable dialkyl ether/poly(hydrogen fluoride) complexes: Dimethyl ether/poly(hydrogen fluoride), a new, convenient, and effective fluorinating agent J. Am. Chem. Soc. 2002, 124, 7728-7736
49. Liang, T.; Neumann, C. N.; Ritter, T. Introduction of fluorine and fluorine-containing functional groups Angew. Chem., Int. Ed. 2013, 52, 8214-8264
50. 50 values in the micromolar range. For the original preparation of 4- N -alkyl-substituted gemcitabine derivatives and their cytotoxic evaluation in CCRF-CEM cell line, see: Hertel, L. W.; Kroin, J. S. 2′-Deoxy-2′,2′-difluoro-(4-substituted pyrimidine) nucleosides having antiviral and anti-cancer activity and intermediates. European Patent Appl. 576230, 1993.
51. Krajewska, E.; Shugar, D. Alkylated cytosine nucleosides: Substrate and inhibitor properties in enzymatic deamination Acta Biochim. Pol. 1975, 22, 185-194
52. Hermida, S. A. S.; Possari, E. P. M.; Souza, D. B.; Campos, I. P. D.; Gomes, O. F.; Di Mascio, P.; Medeiros, M. H. G.; Loureiro, A. P. M. 2′-Deoxyguanosine, 2′-deoxycytidine, and 2′-deoxyadenosine adducts resulting from the reaction of tetrahydrofuran with DNA bases Chem. Res. Toxicol. 2006, 19, 927-936
53. Tang, X. J.; Dmochowski, I. J. Phototriggering of caged fluorescent oligodeoxynucleotides Org. Lett. 2005, 7, 279-282
54. Plitta, B.; Adamska, E.; Giel-Pietraszuk, M.; Fedoruk-Wyszomirska, A.; Naskret-Barciszewska, M.; Markiewicz, W. T.; Barciszewski, J. New cytosine derivatives as inhibitors of DNA methylation Eur. J. Med. Chem. 2012, 55, 243-254
55. Kraszewski, A.; Delort, A. M.; Teoule, R. Synthesis of 4-mono- and dialkyl-2′-deoxycytidines and their insertion into an oligonucleotide Tetrahedron Lett. 1986, 27, 861-864
56. DeGrado, T. R.; Bhattacharyya, F.; Pandey, M. K.; Belanger, A. P.; Wang, S. Y. Synthesis and preliminary evaluation of 18-F-18-fluoro-4-thia-oleate as a PET probe of fatty acid oxidation J. Nucl. Med. 2010, 51, 1310-1317